Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.
复制标题
DOI：
10.1186/ar2794
复制
发表时间：
2009
影响因子：
4.9
通讯作者：
ATLAS study group
中科院分区：
文献类型：
--
作者：
van der Heijde D;Salonen D;Weissman BN;Landewé R;Maksymowych WP;Kupper H;Ballal S;Gibson E;Wong R;Canadian (M03-606) study group;ATLAS study group
强直性脊柱炎（AS）是一种与脊柱炎症相关的慢性风湿病，随后导致结构损伤和功能丧失的进展。全人抗肿瘤坏死因子（anti-TNF）抗体阿达木单抗可减轻活动性AS患者的体征和症状，并改善整体生活质量；这些益处在2年的治疗中一直保持着。我们的目的是比较接受阿达木单抗治疗长达2年的AS患者与未接受TNF拮抗剂治疗的患者脊柱结构损伤的进展。每隔一周皮下注射40mg阿达木单抗的AS患者的x线片来自阿达木单抗试验评估强直性脊柱炎的长期疗效和安全性（ATLAS）研究和加拿大AS研究（M03-606）。使用改良的Stoke AS脊柱评分（mSASSS）方法，将这两项研究（阿达木单抗队列，n = 307）中接受阿达木单抗治疗的患者从基线到2年的脊柱放射学进展与历史上的anti-TNF-naïve队列（AS国际研究[OASIS]的结局，n = 169）进行比较。基于基线和2年x线片，mSASSS结果在阿达木单抗组和OASIS组之间没有显著差异。从基线到2年，OASIS组的mSASSS平均变化为0.9，阿达木单抗组为0.8 (P = 0.771)，表明两组的放射学进展相似。当对符合ATLAS和加拿大研究的基线疾病活动标准的OASIS队列患者（OASIS- eligible队列）的结果进行分析时，OASIS- eligible患者和阿达单抗治疗患者从基线到2年的mSASSS平均变化无显著差异；oasis组的mSASSS平均变化为0.9，阿达木单抗组的mSASSS平均变化为0.8 （P = 0.744）。根据mSASSS评分系统的评估，与患者naïve接受TNF拮抗剂治疗的放射学数据相比，阿达木单抗治疗2年并未减缓AS患者的放射学进展。加拿大研究（M03-606） ClinicalTrials.gov编号：NCT00195819；ATLAS研究（M03-607） ClinicalTrials.gov编号：NCT00085644。
Ankylosing spondylitis (AS) is a chronic rheumatic disease associated with spinal inflammation that subsequently leads to progression of structural damage and loss of function. The fully human anti-tumor necrosis factor (anti-TNF) antibody adalimumab reduces the signs and symptoms and improves overall quality of life in patients with active AS; these benefits have been maintained through 2 years of treatment. Our objective was to compare the progression of structural damage in the spine in patients with AS treated with adalimumab for up to 2 years versus patients who had not received TNF antagonist therapy. Radiographs from patients with AS who received adalimumab 40 mg every other week subcutaneously were pooled from the Adalimumab Trial Evaluating Long-Term Efficacy and Safety for Ankylosing Spondylitis (ATLAS) study and a Canadian AS study (M03-606). Radiographic progression from baseline to 2 years in the spine of adalimumab-treated patients from these two studies (adalimumab cohort, n = 307) was compared with an historic anti-TNF-naïve cohort (Outcome in AS International Study [OASIS], n = 169) using the modified Stoke AS Spine Score (mSASSS) method. mSASSS results were not significantly different between the adalimumab cohort and the OASIS cohort, based on baseline and 2-year radiographs. Mean changes in mSASSS from baseline to 2 years were 0.9 for the OASIS cohort and 0.8 for the adalimumab cohort (P = 0.771), indicating similar radiographic progression in both groups. When results for patients in the OASIS cohort who met the baseline disease activity criteria for the ATLAS and Canadian studies (OASIS-Eligible cohort) were analyzed, there was no significant difference in mean change in mSASSS from baseline to 2 years between OASIS-Eligible patients and adalimumab-treated patients; the mean changes in mSASSS were 0.9 for the OASIS-Eligible cohort and 0.8 for the adalimumab cohort (P = 0.744). Two years of treatment with adalimumab did not slow radiographic progression in patients with AS, as assessed by the mSASSS scoring system, when compared with radiographic data from patients naïve to TNF antagonist therapy. Canadian study (M03-606) ClinicalTrials.gov identifier: NCT00195819; ATLAS study (M03-607) ClinicalTrials.gov identifier: NCT00085644.
登录
查看更多内容
影响因子：
--
作者：
Keystone, EC;Kavanaugh, AF;Chartash, EK
通讯作者：
Chartash, EK
影响因子：
--
作者：
Lories, Rik J. U.;Derese, Inge;Luyten, Frank P.
通讯作者：
Luyten, Frank P.
影响因子：
--
作者：
van der Heijde, D.;Landewe, R.;Davis, J. C., Jr.
通讯作者：
Davis, J. C., Jr.
影响因子：
27.4
作者：
van der Heijde, D.;Schiff, M. H.;Davis, J. C., Jr.
通讯作者：
Davis, J. C., Jr.
影响因子：
--
作者：
van der Heijde, D;Landewé, R;van der Linden, S
通讯作者：
van der Linden, S